Lactococcus lactiscarrying the pValac DNA expression vector coding for IL-10 reduces inflammation in a murine model of experimental colitis
- Meritxell Zurita-Turk†1,
- Silvina del Carmen†2,
- Ana CG Santos3,
- Vanessa B Pereira1,
- Denise C Cara4,
- Sophie Y Leclercq5,
- Alejandra dM de LeBlanc2,
- Vasco Azevedo1,
- Jean-Marc Chatel6,
- Jean G LeBlanc2 and
- Anderson Miyoshi1Email author
© Zurita-Turk et al.; licensee BioMed Central Ltd. 2014
Received: 8 May 2014
Accepted: 4 August 2014
Published: 9 August 2014
Inflammatory bowel diseases (IBD) are intestinal disorders characterized by inflammation in the gastrointestinal tract. Interleukin-10 is one of the most important anti-inflammatory cytokines involved in the intestinal immune system and because of its role in downregulating inflammatory cascades, its potential for IBD therapy is under study. We previously presented the development of an invasive strain of Lactococcus lactis (L. lactis) producing Fibronectin Binding Protein A (FnBPA) which was capable of delivering, directly to host cells, a eukaryotic DNA expression vector coding for IL-10 of Mus musculus (pValac:il-10) and diminish inflammation in a trinitrobenzene sulfonic acid (TNBS)-induced mouse model of intestinal inflammation. As a new therapeutic strategy against IBD, the aim of this work was to evaluate the therapeutic effect of two L. lactis strains (the same invasive strain evaluated previously and the wild-type strain) carrying the therapeutic pValac:il-10 plasmid in the prevention of inflammation in a dextran sodium sulphate (DSS)-induced mouse model.
Results obtained showed that not only delivery of the pValac:il-10 plasmid by the invasive strain L. lactis MG1363 FnBPA+, but also by the wild-type strain L. lactis MG1363, was effective at diminishing intestinal inflammation (lower inflammation scores and higher IL-10 levels in the intestinal tissues, accompanied by decrease of IL-6) in the DSS-induced IBD mouse model.
Administration of both L. lactis strains carrying the pValac:il-10 plasmid was effective at diminishing inflammation in this murine model of experimental colitis, showing their potential for therapeutic intervention of IBD.
Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), are characterized by spontaneous and chronic inflammation of the gastrointestinal tract (GIT). Despite much research in the last years, the exact etiology and pathogenesis of these disorders remain unclear; however, it is nowadays generally accepted that IBD are caused by dysregulation of the mucosal immune system in relation to the native intestinal microbiota in genetically susceptible individuals . Current treatments for IBD are restricted to the use of anti-inflammatory drugs, immunosuppressants and antibiotics, which although showing moderate therapeutic effect, present serious side effects and reveal that better, cheaper and longer lasting drugs are necessary .
Interleukin-10 (IL-10) is one of the most important anti-inflammatory cytokines involved in the intestinal immune system  and because of its immunosuppressive activity and its central role in downregulating inflammatory cascades  it presents itself as a good therapeutic candidate against IBD . Recombinant human IL-10 raised hope when first used in the 90s in CD patients as the treatment led to remission in patients that were otherwise refractory to treatment ; however, two large, multi-centered follow-up studies using subcutaneous dosing were unable to confirm the results [7, 8]. Moreover, systemic treatment with IL-10 showed to be quite limiting because of its short half-life (1.1-2.6 h) and requirement of high protein concentration (20 μg/kg), increasing the cost of production, discomfort and secondary effects in the patients . On the other hand, oral treatment with IL-10 has also shown to be limited due to its extreme sensitivity to the environment of the GIT and therefore survival in it .
New approaches to yield more specific delivery of IL-10 to the intestinal mucosa and prevent the drawbacks associated to systemic and oral administration led to the development of IL-10-producing Lactococcus lactis (L. lactis) strains . In 2003, a biological containment system for human IL-10-producing L. lactis showed to be safe and improved the disease when tested in CD patients in phase I clinical trials ; however, clinical results did not reveal a statistically significant difference in mucosal healing between patients receiving the recombinant strains and placebo.
Since this strain produces IL-10 and releases it in the GIT, its clinical use for IBD is still hindered by IL-10’s sensitivity and poor survival in these hostile conditions. In this regard, a new eukaryotic DNA expression vector for delivery using lactococci, called pValac, which allows cloning of an ORF (Open Reading Frame) of interest, expression of the molecule by host cells, replication both in E. coli and in L. lactis and selection of bacteria, was firstly constructed in 2009 . Its potential to deliver DNA and trigger DNA expression by epithelial cells has already been demonstrated in vitro and in vivo. This strategy does not only fulfil the aforementioned advantages, but also combines the advantages of mucosal immunity, safety of using non-pathogenic bacteria, technique simplicity and low cost of DNA therapy. Moreover, ingested L. lactis strains pose no risk to the individuals as these bacteria are quickly degraded and only around 20-30% reach the sites of inflammation, their transit through the gastrointestinal tract takes between 2 to 3 days and they are incapable of multiplying in the body or become part of the normal gut flora.
Our research group recently evaluated a recombinant invasive L. lactis strain expressing the Staphylococcus aureus Fibronectin Binding Protein A (FnBPA), harbouring the eukaryotic DNA expression vector pValac coding for the anti-inflammatory cytokine IL-10 of Mus musculus (L. lactis MG1363 FnBPA + pValac:il-10), for in situ expression of IL-10 and therefore higher, more efficient and direct production of this cytokine at the sites of inflammation. This strategy showed to be efficient at diminishing inflammation in a TNBS-induced inflammatory mouse model .
The aim of the present work was to evaluate and compare the therapeutic capacity of two L. lactis strains, the invasive L. lactis MG1363 FnBPA + strain and the wt L. lactis MG1363, both carrying the pValac:il-10 plasmid, for the prevention of experimental IBD in a DSS-induced mouse model.
Bacterial strains, growth conditions and plasmid
Bacterial strains used in this work
Escherichia coli (E.coli) TG1
[supE, hsd, ∆5, thi, ∆lac-proAB), F’(traD36 proAB-lacZ∆M15)]
Invitrogen (São Paulo, Brazil)
Escherichia coli (E.coli) TG1 (pValac:il-10)
Lactococcus lactis (L. lactis) MG1363
L. lactis subsp. cremorisb
Laboratory of Cellular and Molecular Genetics (LGCM), Federal University of Minas Gerais (UFMG), Brazil
Lactococcus lactis (L. lactis) MG1363 pValac:il-10
L. lactis MG1363 strain carrying the pValac:il-10 plasmid
Lactococcus lactis (L. lactis) MG1363 FnBPA
L. lactis MG1363 strain expressing FnBPA of S. aureus
Lactococcus lactis (L. lactis) MG1363 FnBPA pValac:il-10
L. lactis MG1363 strain expressing FnBPA of S. aureus carrying the pValac:il-10 plasmid
As previously shown by del Carmen and co-workers, the pValac:il-10 plasmid harbours an eukaryotic region containing the CytoMegaloVirus promoter (pCMV), the IL-10 ORF of Mus musculus and the polyadenylation signal of bovine growth hormone (BGH polyA), required for gene expression by eukaryotic host cells, as well as a prokaryotic region containing the RepA/RepC replication origins for both E. coli and L. lactis, respectively, and a Cm resistance gene for bacterial selection .
General DNA manipulation techniques were carried out according to standard procedures. Unless otherwise indicated, DNA restriction and modification enzymes were used as recommended by the suppliers. DNA fragments were isolated from agarose gels using the Illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare Life Sciences, Chalfont St. Giles, UK). PCR amplifications were performed using AccuPrimePfx DNA Polymerase (Invitrogen, Carlsbad, CA, USA) and/or GoTaq DNA Polymerase (Invitrogen, Carlsbad, CA, USA) in a DNA thermocycler (MJ Research, Inc., Minnesota, USA). Plasmid DNA from E. coli and L. lactis was isolated as previously described  with the following modifications: for plasmid DNA extraction from L. lactis, the first step included addition of TES (25% sucrose, 1 mM EDTA, 50 mMTris-HCl, pH 8) containing lysozyme (10 mg/mL) for 30 min at 37°C to prepare protoplasts. Electroporation of E. coli and L. lactis was performed as previously described . E. coli transformants were plated on LB agar plates containing the required antibiotic for 24 h at 37°C, whereas L. lactis transformants were plated on GM17 agar plates containing the required antibiotic and were counted after 2-days incubation at 30°C.
Induction of intestinal inflammation and feeding procedure in mice
Conventional female C57BL/6 mice  weighing approximately 18 g, obtained from the inbred closed colony (CEBIO) maintained at the Federal University of Minas Gerais (UFMG – Belo Horizonte, Brazil), were used to evaluate the therapeutic effect of L. lactis MG1363 pValac:il-10 and L. lactis MG1363 FnBPA + pValac:il-10 in the prevention of intestinal inflammation in a DSS-induced mouse model. Procedures and manipulation of animals followed the rules of the ethics and research committees of the Biological Institute of the UFMG and all animal protocols were approved by the Ethics Committee on Animal Experiments (CETEA). All animals were maintained in collective cages (6 animals/cage) in an environmentally controlled room with a 12-hour light/dark cycle and unlimited free access to water (or DSS solution) and food. After acclimatization for 17 days, colonic inflammation was induced by the addition of 1.5% (w/v) DSS (MW 40,000-50,000; USB Affymetrix, Santa Clara, CA, USA) in drinking water for 7 consecutive days. Liquid consumption was monitored to ensure that all mouse groups consumed similar volumes (4 ± 2 mL) of the DSS solution daily. For experimental procedure, mice were divided in 6 experimental groups: i) control group which received 100 μl NaCl intragastrically while no DSS was added to the drinking water; ii) DSS group which received 100 μl NaCl intragastrically while DSS was added to the drinking water and iii) L. lactis MG1363 group (wt group), iv) L. lactis MG1363 pValac:IL-10 group, v) L. lactis MG1363 FnBPA + group and vi) L. lactis MG1363 FnBPA + pValac:il-10 group, which all received intragastrically 100 μl of the corresponding bacterial strain as suspension, at a dose of 2×109 CFU/100 μl, in NaCl. The intragastric administration of NaCl or the bacterial suspensions was once daily since the day before the beginning of DSS administration until sacrifice. At day 9, mice were sacrificed by cervical dislocation for organ collection.
Macroscopic and microscopic (histological) assessment of intestinal inflammation
On the day of sacrifice (day 9), colons were removed, excised and visually inspected for macroscopic evaluation to assess colonic inflammation [disease activity index (DAI)], using a scoring system in which the following features were graded: body weight loss (0, no loss; 1, 1-5% loss; 2, 5-10% loss; 3, 11-15% loss and 4, >15% loss), diarrhoea (0, absent; 2, moderate; 4, severe) and rectal bleeding (0, absent; 2, moderate; 4, severe). The macroscopic damage score was calculated from the score of all clinical signs with a maximum score of 12. For histological inflammation scoring [histological activity index (HAI)], samples of the colon were fixed in 10% formalin in phosphate-buffered saline (PBS), embedded in paraffin, cut into 3–5-μm sections and stained with haematoxylin–eosin (H&E-staining) for microscopic analysis. These sections were blindly scored based on a semi quantitative scoring system previously described  in which the following features were graded: extent of destruction of the mucosa’s architecture (0, normal; 1, 2 and 3, light, moderate and extensive damage, respectively), presence and degree of cellular infiltration (0, normal; 1, 2 and 3, light, moderate and transmural infiltration, respectively), extent of muscle thickening (0, normal; 1, 2 and 3, light, moderate and extensive thickening, respectively), presence or absence of crypt abscesses (0, absent and 1, present) and the presence or absence of goblet cell depletion (0, absent and 1, present). The histological damage score was calculated as the addition of the scores corresponding to each feature. High macroscopic and histological damage scores indicate increased damage in the intestines.
Secretory IgA (sIgA) assay
Levels of sIgA in the intestinal fluid were determined by enzyme linked immunosorbent assay (ELISA) as previously described . Briefly, microtitre plates (NUNC, Thermo Scientific, Waltham, MA, USA) were coated with goat anti-mouse UNLB antibody (Southern Biotechnology, Birmingham, AL, USA) in coating buffer (pH 9.8) overnight at 4°C. Wells were then washed with a saline 0.05% tween solution and blocked with 200 μL of PBS with 0.05% (w/v) casein for 1 h at room temperature. The supernatants obtained from the intestinal fluids after centrifugation at 432 g for 20 min at 4°C and the diluted standards in PBS-0.25% casein (1:10) were then added to the plate and incubated for 1 hour at 37°C. After washing, goat anti-mouse IgA HRP (Southern Biotechnology, Birmingham, AL, USA) was added and plates were incubated for 1 h at 37°C. The colour reaction was developed at room temperature with the addition of 100 μL/well of orthophenylenediamine (OPD) (1 mg/mL) (Sigma, St. Louis, MO, USA), 0.04% H2O2 substrate in sodium citrate buffer. The reaction was finally stopped by the addition of 20 μL/well of 2 N H2SO4. Absorbance was measured at 492 nm using a Bio-Rad Model 450 Microplate Reader. Results were expressed as concentration (μg/mL), according to the standard curve.
Colon tissue preparation and cytokine assays
For cytokine assays, colons were weighed and homogenized in PBS containing 0.05% (v/v) Tween-20, 0.1 mM phenylmethylsulphonyl fluoride, 0.1 mM benzethonium chloride, 10 mM EDTA and 20 KIU AprotininA using a tissue homogenizer (1 mL/0.1 g). Suspensions were centrifuged at 600 g for 10 min at 4°C and the supernatants collected for cytokine assay. Concentrations of IL-10, TNF-α, IL-6, IL-17 were measured by ELISA as described previously . Briefly, after coating microtitre plates (NUNC, Thermo Scientific, Waltham, MA, USA) with purified monoclonal antibodies reactive to mouse cytokines IL-10, TNF-α, IL-6, IL-17 (BD, New Jersey, USA), standards and samples were added and incubated overnight at 4°C. Biotinylated monoclonal antibodies anti-mouse IL-10, TNF-α, IL-6, IL-17 were added and incubated for 1 h at room temperature, after which peroxidase-labelled streptavidin (Sigma, St. Louis, MO, USA) was added. A colour reaction was developed at room temperature with 100 μL/well of OPD (1 mg/mL) and 0.04% H2O2 substrate in sodium citrate buffer. The reaction was stopped by the addition of 20 μL/well of 2 N H2SO4. Absorbance was measured at 492 nm using a Bio-Rad Model 450 Microplate Reader. Results were expressed as concentration of each cytokine (pg/mL), according to the respective standard curve.
Statistical analyses were performed using the GraphPad Prism 5.0 software (San Diego, CA, USA) and all results were expressed as mean ± standard deviation (SD). Significance of differences among groups was assessed by Student’s t-test or analysis of variance (ANOVA) followed by a Tukey comparison post-hoc test. Means were considered statistically different when p < 0.05.
Construction of L. lactis MG1363 pValac:il-10
The pValac:il-10 plasmid was previously constructed by del Carmen and co-workers and used to construct the invasive L. lactis MG1363 FnBPA + pValac:il-10 strain. This strain was tested in an experimental IBD mouse model induced by TNBS and showed to diminish inflammation and damage scores . In this work, we constructed the non-invasive L. lactis MG1363 pValac:il-10 strain; the construction was confirmed by PCR (data not shown). This strain was tested together with the invasive strain in the experimental IBD mouse model induced by DSS.
L. lactis strains carrying the pValac:il-10plasmid show anti-inflammatory properties in the DSS-induced colitis in mice
DSS is a well-established animal model of mucosal inflammation that has been used for over two decades in the study of IBD pathogenesis and preclinical studies  and when administrated in drinking water induces an acute inflammation. C57BL/6 mice were used for the DSS study as these animals are highly susceptible to DSS-induced colitis and do not naturally recover from this disease .
To evaluate the colons microscopically, a HAI was performed for all groups, and showed that animals from the pValac:il-10 groups presented a significant decrease of the damage score when compared to the DSS group and the mice that received L. lactis MG1363 or L. lactis MG1363 FnBPA + (Figure 2A).
Histologically, all samples from the colon of healthy control mice (group without DSS treatment) presented themselves within normal standards. The architecture integrity of the colon was maintained, with goblet cells, thin submucosa without signs of congestion or oedema and absence of inflammatory infiltrate in the mucosa and submucosa (Figure 2B). On the other hand, the colitis control group (DSS group, Figure 2C) presented intense alteration in the mucosal architecture of their colons, with areas of intense ulceration, absence of glands in large parts of the mucosa and accentuated depletion of goblet cells. It was also possible to observe crypt abscesses and the submucosa was marked by an intense oedema and inflammatory infiltrate constituted principally by macrophages. Moreover, thickening of the muscle layer was also observed. No significant differences were observed when animals received L. lactis MG1363 (Figure 2D) or L. lactis MG1363 FnBPA + (Figure 2F) strains, compared to the DSS treated control. However, groups that received L. lactis MG1363 pValac:il-10 (Figure 2E) or L. lactis MG1363 FnBPA + pValac:il-10 (Figure 2G) presented a milder pathological picture, with tendency to normality, a smaller compromised area and a reduction in the intensity of the lesion. Reduced inflammatory infiltrates without erosion of the epithelium, light oedema and diminished depletion of goblet cells, partially preserving the mucosal architecture, were also observed.
The pValac:il-10plasmid increases the production of secretory IgA
The administration of L. lactis carrying the pValac:il-10plasmid modulates the production of cytokines in the intestinal tissues
Interleukin 10’s interest in the attempt of developing an efficient therapy against IBD has grown since it was observed that IL-10 knockout (IL-10−/−) mice develop spontaneous enterocolitis when not maintained in germ-free conditions . Although many advances have been made there still does not exist any treatment for IBD, showing that the major drawback to use IL-10 is its correct administration and directioning to the sites of inflammation.
In order to overcome these problems, new strategies based on local delivery of IL-10 to the intestinal mucosa have been developed; high IL-10 concentration at these sites would outweigh the need for high doses and as such avoid the increase of pro-inflammatory cytokine production and other undesired side effects.
One such strategy consists in the use of polymer-based microparticles. These particles encapsulate gelatine nanoparticles containing plasmid DNA expressing murine IL-10 and are capable of releasing these nanoparticles directly at the desired site of action. These IL-10 gene containing particles have shown to successfully reduce the levels of inflammatory cytokines as well as disease activity scores in the TNBS-induced model of colitis . However, despite promising, scale-up to an industrial level appears to be very expensive and complicated.
Another strategy by Yao and collaborators consists in a Bifidobacterium longum strain capable of secreting human IL-10 which was capable of alleviating inflammatory damage of colonic tissue in a DSS-induced mouse model by blocking the colitis-activated NF-κB pathways and upregulating CD4 + CD25 + Foxp3+ Treg in blood and mesenteric lymph nodes .
As such, in order to improve IL-10 delivery to the sites of inflammation using L. lactis, a L. lactis strain expressing FnBPA [15, 28], that has the capacity to efficiently internalize and trigger recombinant DNA expression by human epithelial cells, was used to deliver a eukaryotic expression vector coding for IL-10 of Mus musculus, pValac:il-10, directly to host cells in the GIT for recombinant in situ IL-10 production. This new strategy recently showed to be capable of diminishing inflammation in a TNBS-induced mouse model .
Following these results and in order to evaluate the therapeutic effect of the pValac:il-10 plasmid in a larger context, in the present work we explored the potential of this therapeutic plasmid in a DSS-induced mouse model delivered by two L. Lactis strains as a new therapeutic strategy for the prevention of intestinal inflammation. L. lactis MG1363 FnBPA + expresses FnBPA, which confers the strain the capacity to mediate adhesion to host tissue and bacterial uptake by eukaryotic cells. To evaluate if this characteristic results in improved anti-inflammatory effect, it was compared with the non-invasive L. lactis MG1363 strain. Our results showed that both strains were capable of delivering the eukaryotic expression vector to host cells directly at the sites of inflammation leading to in situ IL-10 production, avoiding strong and undesired side-effects, and diminishing the severity of inflammation by maintaining an anti-inflammatory environment in the gut.
DSS has the intrinsic capacity to disrupt the epithelial cell barrier, causing normal gut substances to activate mucosal macrophages, which in turn produce immunomodulatory cytokines. It is generally accepted that DSS is directly toxic to gut epithelial cells of the basal crypts and affects the integrity of the mucosal barrier . The DSS concentration used in the present model triggered an acute colonic inflammation accompanied by diarrhoea and rectal bleeding and did not lead to mortality. The administration of strains carrying the pValac:il-10 plasmid statistically lowered the macroscopic score compared to the DSS group, regarding diarrhoea and rectal bleeding. No weight loss was observed within the different groups, but this has already been reported earlier . At histological level, administration of strains carrying the pValac:il-10 plasmid were capable of decreasing the severity of inflammation, with tendency to normality, demonstrating the anti-inflammatory effects of this strategy.
IgA is the most abundant immunoglobulin produced, in its secretory form, at mucosal sites. In the luminal mucous layer, sIgA protects the intestinal epithelium against colonization and invasion by pathogens or commensals  and therefore helps modulating and controlling inflammation. In our model, no significant decrease of sIgA was associated with the inflammation observed in mice treated with DSS that did not receive the pValac:il-10. The administration of bacteria carrying the pValac:il-10 plasmid was accompanied by significantly increased levels of sIgA only in the intestinal fluid of mice that received the L. Lactis MG1363 FnBPA + pValac:il-10 strain, compared to the DSS treated mice. Moreover, this strain also induced an increased sIgA production when compared to the L. lactis MG1363 pValac:il-10 strain. We believe that the difference of IgA production induced by these two strains is due to the different cellular entry mechanism these bacteria use after oral administration. In this regard, L. lactis MG1363 FnBPA + pValac:il-10 strain induced increased IgA production because these bacteria invade enterocytes in the epithelium, while L. lactis MG1363 pValac:il-10 are captured by macrophages (as these bacteria have no invasion capacity), which does not directly lead to the induction of IgA. These results showed that the L. Lactis MG1363 FnBPA + pValac:il-10 strain could not only have an anti-inflammatory effect in this model, but also promote the gut immunological barrier by limiting the penetration of bacteria into host tissues and therefore protect mice by helping to modulate inflammation. The expression of FnBPA by this strain might allow for a higher binding capacity and internalization by eukaryotic cells, thus enhancing the production of IL-10 and its anti-inflammatory properties.
Cytokines produced in the gut mucosa greatly influence the resulting immunological outcome; production of anti-inflammatory cytokines induces mucosal tolerance, while high levels of pro-inflammatory cytokines induce inflammation. Since cytokines are major mediators of inflammation and regulatory activity in the gut mucosa, we analysed the ability of L. lactis strains carrying the pValac:il-10 plasmid to modulate the production of cytokines in the colonic tissues of mice. Mice that received the pValac:il-10 plasmid, whether delivered by L. lactis MG1363 or L. lactis MG1363 FnBPA + (pValac:il-10 groups), showed significantly higher IL-10 levels than the control group (healthy mice), probably due to a constant and higher production of IL-10 by the eukaryotic cells of these animals. It is also important to note that the expression of FnBPA by the bacterial strain carrying the pValac:il-10 plasmid was associated to significantly higher IL-10 levels in the intestinal tissues compared to the DSS group, where this cytokine was produced as normal immune response against inflammation. However, these levels of IL-10 were not significantly different from those obtained in the L. lactis MG1363 pValac:il-10 group, nor were associated with significant differences in the levels of the other cytokines tested in both pValac:il-10 groups. The lack of significant difference between both strains carrying the pValac:il-10 plasmid could be explained by the fact that both cellular entry mechanisms used by these bacteria (enterocytes invasion by the invasive strain and capture by macrophages by the non-invasive strains) lead to efficient and similar IL-10 production; however, by different cell types.
Pro-inflammatory cytokines, including TNF-α, IL-6 and IL-17, can be produced by T and B lymphocytes, macrophages and/or neutrophils, which are massively infiltrated in inflammatory lesions in mice with DSS-induced acute colitis. This DSS colitis switches from a Th1-Th17-mediated acute inflammation with increased levels of TNF-α, IL-6 and IL-17, to a predominant Th2-mediated inflammatory response that shows a decrease in TNF-α, IL-6 and IL-17 while increasing levels of anti-inflammatory cytokines IL-4 and IL-10 . In our experimental acute model, at the time of sacrifice, the results only showed higher IL-6 levels in the DSS group and in the group of mice treated with DSS that received the L. lactis MG1363 strain, when compared to the control group (healthy mice). Significant decrease of this cytokine was observed in the intestinal tissues from mice that received the pValac:il-10 plasmid, compared to the DSS group. These results were associated to the increased IL-10 levels obtained in those animals and confirm the anti-inflammatory capacity of both strains carrying the pValac:il-10 plasmid at modulating the gut immune response.
The results obtained in the present work confirm and strengthen our previous results that L. lactis MG1363 FnBPA + pValac:il-10 shows to be a good candidate to maintain an anti-inflammatory status in the GIT and diminishing intestinal inflammation. Moreover, we here also showed that not only delivery of the pValac:il-10 plasmid by the invasive strain L. lactis MG1363 FnBPA+, but also by the non-invasive L. lactis MG1363 strain, was effective at diminishing intestinal inflammation, showing that this strategy presents potential for therapeutic intervention of IBD. FnBPA expression was not related to more anti-inflammatory capacity; however, it was associated with significantly higher IL-10 levels in the intestinal tissues when compared to animals from the DSS group. Moreover, the highest levels of sIgA in the intestinal fluid where observed in the animals from the L. lactis MG1363 FnBPA + pValac:il-10 group, showing better immunomodulatory effect by the invasive strain.
Jean G LeBlanc and Anderson Miyoshi Share credit in this work for senior authorship.
This work was supported by: (i) Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), (ii) Centro Brasileiro-Argentino de Biotecnologia (CBAB), (iii) Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), (iv) Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), (v) Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT) and (vi) Consejo de Investigaciones de la Universidad Nacional de Tucumán (CIUNT).
- Fiocchi C: Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998, 115: 182-205.View Article
- Lakatos L, Lakatos PL: Changes in the epidemiology of inflammatory bowel diseases. Orv Hetil. 2007, 148 (5): 223-228.View Article
- Asadullah K, Sterry W, Volk HD: Interleukin-10 therapy—review of a new approach. Pharmacol Rev. 2003, 55 (2): 241-269.View Article
- Mocellin S, Marincola F, Rossi CR, Nitti D, Lise M: The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev. 2004, 15 (1): 61-76.View Article
- de Moreno de LeBlanc A, del Carmen S, Zurita-Turk M, Santos Rochat C, van de Guchte M, Azevedo V, Miyoshi A, LeBlanc JG: Importance of IL-10 modulation by probiotic microorganisms in gastrointestinal inflammatory diseases. ISRN Gastroenterol. 2011, 1 (1): 1-10.View Article
- Van Deventer SJH, Elson CO, Fedorak R: Multiple doses of intravenous interleukin 10 in steroid-refractory crohn’s disease. Gastroenterology. 1997, 113: 383-389.View Article
- Colombel FF, Rutgeerts P, Malchow H, Jacyna M, Nielsen OH, Rask-Madsen J, Van Deventer S, Ferguson A, Desreumaux P, Forbes A, Geboes K, Melani L, Cohard M: Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn’s disease. Gut. 2001, 49: 42-46.View Article
- Schreiber S, Fedorak RN, Nielsen OH: Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn’s disease. Crohn’s disease IL-10 cooperative study group. Gastroenterology. 2000, 119: 1461-1472.View Article
- Van Montfrans C, Van de Ende A, Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, Hanauer S, Grint P, Van Deventer SJH: Anti- and proinflammatory effects of interleukin 10 in mild to moderate Crohn’s disease. Gastroenterology. 1999, 116: A777-View Article
- Steidler L, Vandenbroucker K: Genetically modified Lactococcus lactis: novel tools for drug delivery. Int J Dairy Technol. 2006, 59 (2): 140-146.View Article
- Li MC, He SH: IL-10 and its related cytokins for treatment of inflammatory bowel disease. World J Gastroenterol. 2004, 10 (5): 620-625.View Article
- Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, Cox E, Remon JP, Remaut E: Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol. 2003, 21: 785-789.View Article
- Braat H, Rottiers P, Hommes DW: A phase I Trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin Gastroenterol Hepatol. 2006, 4 (6): 754-759.View Article
- Guimarães V, Innocentin S, Chatel JM, Lefevre F, Langella P, Azevedo V, Miyoshi A: A new plasmid vector for DNA delivery using lactococci. Genet Vaccines Ther. 2009, 10 (7): 4-View Article
- Innocentin S, Guimarães V, Miyoshi A, Azevedo V, Langella P, Chatel JM, Lefevre F: Lactococcus lactis expressing either Staphylococcus aureus fibronectin-binding protein A or Listeria monocytogenes internalin A can efficiently internalize and deliver DNA in human epithelial cells. Appl Environ Microbiol. 2009, 75: 4870-4878.View Article
- Pontes D, Innocentin S, del Carmen S, Franco Almeida J, LeBlanc JG, de Moreno de LeBlanc A, Blugeon S, Cherbuy C, Lefèvre F, Azevedo V, Miyoshi A, Langella P, Chatel JM: Production of fibronectin binding protein A at the surface of Lactococcus lactis increases plasmid transfer in vitro and in vivo. PLoS One. 2009, 24: 1-9.
- del Carmen S, Zurita-Turk M, Lima A, Coelho dos Santos JS, Leclercq SY, Chatel JM, Azevedo V, De Moreno de LeBlanc A, Miyoshi A, LeBlanc JG: A novel interleukin-10 DNA mucosal delivery system attenuates intestinal inflammation in a mouse model. EurJ Inflamm. 2013, 11 (3): 641-654.
- Que YA, Francois P, Haefliger JA, Entenza JM, Vaudaux P, Moreillon P: Reassessing the role of Staphylococcus aureus clumping factor and fibronectin-binding protein by expression in Lactococcus lactis. Infect Immunol. 2001, 69: 6296-6302.View Article
- Sambrook J, Fritsch EF, Maniatis T: Molecular cloning: a laboratory manual. 1989, Cold Spring Harbor: Cold Spring Harbor Press
- Langella P, Le Loir Y, Ehrlich SD, Gruss A: Efficient plasmid mobilization by pIP501 in Lactococcus lactis subsp. lactis. J Bacteriol. 1993, 175: 5806-5813.
- Melgar S, Bjursell M, Gerdin AK, Svensson L, Michaëlson E, Bohlooly-Y M: Mice with experimental colitis show an altered metabolism with decreased metabolic rate. Am J Physiol Gastrointest Liver Physiol. 2007, 292 (1): G165-G172.View Article
- McCafferty DM, Sihota E, Muscara M, Wallace JL, Keith A, Sharkey KA, Kubes P: Spontaneously developing chronic colitis in IL-10/iNOS double-deficient mice. Am J Physiol Gastrointest Liver Physiol. 2000, 279 (1): G90-G99.
- Maron R, Hancock WW, Slavin A, Hattori M, Kuchroo V, Weiner HL: Genetic susceptibility or resistance to autoimmune encephalomyelitis in MHC congenic mice is associated with differential production of pro- and anti-inflammatory cytokines. Int Immunol. 1999, 11 (9): 1573-1580.View Article
- Alex P, Zachos NC, Nguyen T, Gonzales L, Chen T-E, Conklin LS, Centola M, Li X: Distinct cytokine patterns identified from multiplex profiles of murine dss and tnbs-induced colitis. Inflamm Bowel Dis. 2009, 15 (3): 341-352.View Article
- Kühn R, Lohler J, Rennick D, Rajewsky K, Muller W: Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993, 75: 263-274.View Article
- Bhavsar MD, Amiji MM: Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther. 2008, 15: 1200-1209.View Article
- Yao J, Wang J-Y, Lai M-G, Li Y-X, Zhu H-M, Shi R-Y, Mo J, Xun A-Y, Jia C-H, Feng J-L, Wang L-S, Zeng W-S, Liu L: Treatment of mice with dextran sulfate sodium-induced colitis with human interleukin 10 secreted by transformed bifidobacterium longum. Mol Pharm. 2011, 8: 488-497.View Article
- Pontes DS, de Azevedo MS, Chatel JM, Langella P, Azevedo V, Miyoshi A: Lactococcus lactis as a live vector: heterologous protein production and DNA delivery systems. Protein Expr Purif. 2011, 79 (2): 165-175.View Article
- Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R: A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990, 98 (3): 694-702.
- Hamilton MJ, Sinnamon MJ, Lyng GD, Glickman JN, Wang X, Xing W, Krilis SA, Blumberg RS, Adahi R, Lee DM, Stevens RL: Essential role for mast cell tryptase in acute experimental colitis. Proc Natl Acad Sci. 2011, 108 (1): 290-295.View Article
- Macpherson AJ, Harris NL: Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol. 2004, 4 (6): 478-485.View Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.